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ABSTRACT The role of proteases in cancer is far more complex than initially anticipated and include tumor
promoting as well as suppressive effects and their inhibitors are emerging with promising therapeutics in cancer
treatment. Proteases are involved in tumor growth both at the primary and metastatic sites. Inhibitors of all the five
classes of proteases (serine, aspartyl, cysteine, metallo- and threonine) have been widely reported from plant, animal
and microbial origin. Each protease exhibits a characteristics “recognition–specificity” and are specific to cleave
proteins with a particular structure. Such a capability allows identifying signatures of protease activity in biological
fluids. Individual pattern of protease expression help in easy prognosis and therapeutic administration of specific
protease inhibitor. With the advance of surface enhanced laser desorption ionization time-of-flight (SELDI-TOF)
mass spectrometry, proteomic technologies are directly applied into clinical diagnostic tests. The substrate phage
technology can be used to develop protease profile signatures for all type of cancers. Recently, application of
biomarkers in cancer treatment has become increasingly target-oriented. Gene expression signatures in cancer
provide molecular phenotype that identifies tumor classification not evident by traditional histo-pathological methods.
The current review deals with the role of proteases, their inhibitors in cancer especially in tumor progression,
invasion/metastasis and also addresses the therapeutic approaches, viable strategy for cancer treatment and regime of
the future drug development.
INTRODUCTION
Recent studies have shown that proteases
are involved in progression, tumor growth both
at the primary and metastatic sites. Extracellular
proteases may co-operatively influence matrix
degradation and tumor cell invasion through
proteolytic cascade with individual protease
having distinct roles in tumor growth, invasion,
migration and angiogenesis (Koblinski et al.
2000). Proteases (PRs) are expressed in the
extracellular milieu as inactive proforms that are
activated through a variety of mechanisms, which
often involve a close collaboration among several
families of PRs (Coussens et al. 2002).
There is a positive correlation between the
aggressiveness of a tumor and the secretion of
various PRs. Approximately 500-600 proteases
have been known to exist in human and mouse
genome but not all of them have been found to
be linked with cancer (Puente et al. 2003).
Multiple alterations in a normal cell can lead to a
localized tumor and finally to one that has the
ability to invade and metastasize. Tumor cell
invasion involves attachment of tumor cells to
the underlying basement membrane, local
proteolysis and migration of tumor cells through
its modified region (Liotta et al. 1983). PRs, which
are expressed in these cells, are believed to
participate in many of these steps (Fig. 1).
PRs such as aspartic, cysteine, serine and
metalloproteinases are crucial in cancer
propagation and inhibitors of such enzymes are
emerging with promising therapeutic uses.
Aspartic proteases such as cathepsin D and E,
matrix metalloproteinases (MMPs) and serine
proteases have been studied the most, and they
affect tumor progression in many stages.
Epigenetic changes that occur in normal
epithelial cells (NEC) lead to tumor formation and
growth. Tumor cells (TC) also undergo epithelial-
mesenchymal transformation during the same
time. Formation of neovessel is stimulated where
endothelial cells (EC) proliferate and invade
towards the tumor site. TC also invades the
connective tissue and then intravasate. The TC
must arrive in circulation, arrest, extravasate,
invade the local environment and grow to set up
distant metastasis. These metastasis steps occur
through the interactions of TC, EC, fibroblasts
and invading inflammatory cells (IC), such as
macrophages and the extracellular matrix. Steps
where PRs are believed to participate in this
process are shown in solid arrow.RACHNA PANDEY, NITIN PATIL AND MALA RAO 68
Recently, developed functional genomic
approaches, such as DNA microarrays have
enabled researchers to determine the expression
level of every gene in a given cell or cancer
population, which represents that cell
population’s entire transcriptome.  cDNA array
allows us to define specific molecular pathways
of tumoral progression and to define markers of
prognostic and diagnostic relevance which
reflects significantly on cancer diagnostics and
consequently its management. They also boost
our knowledge of the molecular events
responsible for the development and progression
of cancer (Polyak and Riggins 2001).
Proteases Involved in Tumor Invasion and
Metastasis of Cancer
PRs, which promote or directly contribute to
the degradation and remodeling of the basement
membrane and extracellular matrix are considered
most important in metastasis and angiogenesis
(Bernstein and Liotta 1994). Cysteine protease
such as cathepsin B, L, K, Q, S and aspartic
proteases-cathepsin D and E are mainly involved
in intracellular proteolysis within lysosomes.
Plasmin urokinase type plasminogen activator
belongs to serine protease and gelatinase A
(MMP2) and B (MMP9) of matrix metallopro-
teases are the other proteases responsible for
extracellular proteolysis. Threonine protease
(proteasomes), has the task of eliminating cellular
proteins, tagged for degradation through a
complex modification termed polyubiquitini-
zation. It is a process of addition of a series of
ubiquitin molecules to another protein, targeted
for degradation (Mitchell, 2003). Proteases
families involved in tumor invasion and
metastasis are given in Table 1.
Cathepsin D is one of the most widely studied
acid PRs in cancer research, it not only facilitates
tumor progression but may have a prognostic
value in patients with breast cancer. Human
cathepsin D is an intracellular aspartic proteinase
mainly found in lysosomes. It has a number of
house keeping functions including degradation
of cellular or phagocytosed proteins for repro-
cessing. Chemokines are a family of structurally
related glycoproteins with potent leukocyte
activator and/or has chemotactic activity but
very limited information is available on the
interaction between chemokines and PRs (Vicari
2002).
Cathepsin D is known to degrade chemokines
and consequently affect their putative functions
in the tumors (Wolf et al. 2003). Investigators are
targeting the overexpression of PRs in tumors
by developing novel clinical prodrugs, which are
Fig. 1. The role of PRs in the metastatic process
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inactive until activated by PRs. Cathepsin E is
neither secretary nor lysosomal but it is located
in endoplasmic reticulum/ trans-Golgi network/
endosomal compartments of cells (Kageyama
1998). Aoki et al. (1995), reported conversion of
cathepsin E (CE) to enzymatic unstable form i.e.
medium moving proteinase (Med.P) in gastric
cancer cells and Med.P is a monomeric form of
this protease (CE).CE is also expressed in
pancreatic cancer (Azuma et al. 1995).
Cathepsin L has been implicated in tumor
metastasis, the process where tumor cells detach
from the primary lesion and migrate through
lymph or blood vessels to form new foci at distant
sites (Navab et al. 1997). Cathepsin B was the
first lysosomal protease to be associated with
breast carcinoma (Poole et al. 1978). Procathepsin
B (proCB) gets activated by tissue plasminogen
activator (tPA), which results in activation of
plasmin and MMPs which leads to degradation
of components of extracellular matrix.
Procathepsin B (proCB) may be activated by tPA
initiating a proteolytic cascade which results in
the activation of plasmin and MMPs. Collective-
ly, active proteases can degrade all components
of the extracellular matrix (Fig. 2). The involvement
of cathepsin in regulation of angiogenesis reveals
Metalloproteinases Matrix metalloproteinases,
collagenases (MMP-1,-8 and –13),
gelatinase (MMP-2,-9), matrilysins
(MMP-7,-26, MT- MMPs (MMP
14,-17,-24,-26, stromelysin
(MMP-3,-10,-11), other MMPs
(MMPs-12,-19,- 20, 23- 27 and –
28) and  A Disintegrin And Metallo-
protease (ADAMS)
Serine proteinase Cathepsin G, chymase,
chymotrypsin, membrane bound
serine proteases, elastase, plasmin,
plasminogen activators, trypsins,
tryptase and Human tissue
Kallikreins.
Other proteinase Aspartic proteases (cathepsin D
and E), cysteine proteases
(cathepsin B,H,K,L,M,N,Q,O, S),
caspases (bleomycin hydrolases)
and threonine proteases
(proteasome)
Table 1: Proteases involved in tumor invasion and
metastasis
Fig. 2. Cascade of proteolytic activation
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1989), lungs (Sukoh et al.1994) prostate (Sinha et
al. 1995), glioma (Rempel et al.1994) melanomas
(Rozhin et al. 1994) and oestoclastomas (Page et
al. 1992), suggesting that PRs might be involved
in the development, invasion and metastasis of
more than one type of tumor. Local extracellular-
matrix degradation by proteolytic enzymes is an
important feature of tumor invasion and metastasis
of malignant solid tumors (Fidler, 1990). Plasmin
and urokinase-type plasminogen activator (uPA)
play a central role in cancer cell invasion (Mignatti
and Rifkin 1993). Trypsinogens are serine PRs that
play a significant role in tumor progression. The
production of tumor-associated trypsinogen
(TAT-2) has been correlated with malignant
phenotype (Koivunen, et al. 1990). The
expression of many of the membrane anchored
serine proteases is widely dys-regulated during
tumor growth and progression. The first
membrane anchored serine protease discovered
is enteropeptidase (enterokinase) and matriptase3
is the one of the most novel ones (Netzl-Arnett
et al. 2003).
Eighteen zinc containing endoproteinases,
referred to as matrix metalloproteinases (MMPs),
are collectively capable of degrading collagen,
proteoglycan and produced by variety of cells
(Goetzl et al. 1996; Cawston 1995).  It plays an
important role in normal tissue remodeling and
may also contribute to the local growth of tumors
and the development of metastasis because of
the role they play in tumor cell invasion and
angiogenesis (De Clerck et al. 1994). Also, these
enzymes have been associated with the
progression of diseases in a number of malignan-
cies, including breast, colorectal, gastric,
pancreatic and non small cell lung (NSCL) cancers
(Basset et al. 1993; Hewitt et al. 1991; Ray and
Stetler-Stevenson 1994). At present, 24 different
vertebrate MMPs have been identified, 23 of
which have been found in humans (Visse and
Nagase, 2003). The involvement of MMP-2
(gelatinase A) and MMP-9 (gelatinase B) is well
documented in breast, ovarian, colorectal and
lung tumors (Brown and Giavazzi 1995).
Masson et al. (1998) suggested that MMPs
are involved in early alterations leading to tumor
formation. Mice deficient in stromelysin-3  exhibit
lower tumor incidence and tumor size after
carcinogen treatment. Over expression of some
MMPs leads to development of pre-malignant
and pre-neoplastic lesions (Sympson et al. 1995),
suggesting that MMPs participate in different
stages of tumor progression prior to invasion
and metastasis (Wilson et al. 1997). They are
known to increase cell proliferation by activating
growth factors or liberating them from the ECM
where they are sequestered. Growth factors like
bFGF, EGF, IGF, TGF-b and VEGF are bound to
ECM and can be released upon proteolysis of
the extracellular matrix (ECM) components
(Taipale and Keski-Oja 1997; Whitelock et al.
1996). Noel et al. (1993) showed that the ability of
fibroblasts to promote tumorigenecity of MCF7
cells requires matrigel containing low molecular
weight factors.MMP inhibitors abolish the tumor
promoting effects of the fibroblasts, suggesting
that MMPs from the fibroblasts release growth
factors from the matrigel.
A family of membrane anchored PRs called
‘A Disintegrin And Metallo-protease (ADAM)
proteins have emerged as the major proteinase
family that mediates ectodomain shedding, the
proteolytic release of extracellular domains from
their membrane bound precursors. ADAMs bind
to integrins, inhibit tissue inhibitor metallo-
proteinase (TIMP) activity and affect intracellular
signaling through ectodomain shedding (Huovila
et al. 2005). ADAMs are proteins that contain
both a disintegrin and metalloproteases domain
and have potential implications for the metastasis
of human cancer cells via cell adhesion and
protease activity.ADAM-17/TACE is the best
characterized molecule of the ADAMs family,
since it is involved in the proteolytic cleavage of
the soluble form of tumor necrosis factor a (TNF-
a) (Karan et al.2003).
Proteasomes and human tissue kallikreins (hks)
are the recent emerging targets for therapeutics.
The ubiquitin-proteasome pathway is responsible
for most eukaryotic intracellular protein digestion.
This pathway has been validated as a target for
antineoplastic therapy using both in vitro and
preclinical models of human malignancies and is
influenced as part of the mechanism of action of
certain chemotherapeutic agents (Orlowski and
Claire Dees 2003). The proteasome is responsible
for the degradation of all short-lived proteins and
70-90% of all long- lived proteins (Pajonke and
McBride 2001). The hks are primarily known for
their clinical applicability as cancer biomarkers,
recent evidences indicates hks in many cancer
related processes, including cell growth regu-
lation, angiogenesis, invasion and metastasis.
They have been shown to promote or inhibit
neoplastic progression, acting individually and /PROTEASES AND PROTEASE INHIBITORS 71
or in cascades with other hks and other proteases
and might represent attractive targets for
therapeutic interventions (Borgono and
Diamandis 2004). Prostate-specific antigen (PSA,
hk3) and human glandular kallikreins (hk2) are
widely used tumor markers for prostate cancer.
Three other kallikreins, hk6, hk10 and hk11, are
emerging new serum biomarkers for ovarian,
prostate cancer diagnosis and prognosis
(Diamandis and Yousef 2002).
Protease Inhibitors in Antitumorigenesis
The five major classes of protease enzymes
selectively catalyze the hydrolysis of polypeptide
bonds and are crucial for disease propagation
and inhibitors of such proteases are emerging
with promising therapeutic uses in the treatment
of diseases like cancers. Protease inhibitors can
suppress several stages of carcinogenesis,
including initiation, promotion and progression,
although their mechanism of action is not yet
fully clear. Inhibitors of aspartic peptidases are
relatively uncommon and are found in only a few
specialized locations (Bennette et al. 2000). Few
of the examples include a 17kDa inhibitor of
pepsin and Cathepsin E from the parasite Ascaris
lumbricoides (Kageyama 1998; Ng et al. 2000),
proteins from plants such as potato, tomato and
squash (Christeller et al. 1998) and a pluripotent
inhibitor from sea anaemone of cysteine
peptidase as well as cathepsin D (Lenarcic and
Turk 1999) (Table 2).
BBI, the soybean derived PRs inhibitor is a
potent chymotrypsin inhibitor that has been
extensively studied as this is the PRs inhibitor
that has risen to the human trial stage as a human
cancer chemopreventive agent (Fernandes and
Banerji 1997). Pepstatin, a low –molecular weight
aspartic peptidase inhibitor, isolated from various
sp. of Streptomyces , is a specific inhibitor of
pepsin (Umezawa et al.1970) and cathepsin D
belong to this class of aspartic peptidase
inhibitors. Relatively few inhibitors of cathepsin
D have been reported, partly because of its
uncertain role as a viable target for therapeutic
intervention.
Tolcher et al. (2001) discussed the current
status of PRs inhibitors as cancer chemo-
preventive agents. They report on the present
evaluation, both preclinical and clinical, of the
intervention of soy PRs inhibitors that reduce
superoxide-induced DNA damage in prostate
cancer prevention. A large number of PRs
inhibitors have been isolated from potatoes and
related plants. The potato PRs inhibitors that have
been purified and extensively characterized fall
into three main categories. Inhibitor I, II and
carboxypetidase inhibitor. Potato I inhibitor family
is also referred to as chymotrypsin inhibitor I,
because its specificity is directed most strongly
towards chymotrypsin, although it inhibits
subtilisin, pronase as well as some other alkaline
microbial PRs and it is also a weak inhibitor of
trypsin. Trypsins are widely expressed in various
tissues and cancer cells (Kato et al. 1998). The
potato carboxypeptidase inhibitor is an epidermal
growth factor (EGF) antagonist that inhibits tumor
cell growth (Blanco-Aparicio et al.1998). Aprotinin
has been shown to control plasmin activity
involved in tumor-cell spreading and to prevent
tumor invasion (Verstraete 1985).
Peptidic inhibitors of great interest are
epoxysuccinyl derivatives such as E-64, isolated
Table 2: Protease inhibitors implicated in cancer.
Inhibitor Source Enzyme Disease Reference
17kDa inhibitor A. lumbricoides Pepsin Cathepsin E Cancer Kageyama (1998)
Pluripotent Sea anemone Cathepsin D Cancer Lenarcic and Turk 1999
Bortezomib (PS-341) Synthetic Proteasome Prostatic cancer Voorhees et al. 2003
Bowman–Birk Soybean Cathepsin D Gastric cancer Fernandes and
   inhibitor (BBI) Banerji 1997
BMS 275291 Synthetic MMPs 1,2,,8,9,13, Lung cancer Shepherd (2001)
14 and 3
AE-941 (Neovastat) Shark cartilage MMP-2, MMP-12 NSCLC Gingras et al. 2004
  extract
BB2516 (Marismastat) Synthetic MMP-1, 2, 7, 8, 9 Breast cancer Summers and
NSCLC, glioma Davidsen, 1998
MR889 Synthetic Neutrophil elastase NSCLC Luisetti (1996)
Col-3, CMT-3 Synthetic Gelatinase Glioblastoma, Acharya  (2004)
(Metastat) (MMP-2,9) Kaposi’s sarcomaRACHNA PANDEY, NITIN PATIL AND MALA RAO 72
from cultures of Aspergillus japonicus that
alkylate the active site residue of cysteine
proteases. E-64 is a broad-spectrum inhibitor,
which also effectively inhibits cathepsin L and
calpain. This inhibitor supports development of
cathepsin L inhibitors as potential therapeutics
as antimetastatic agents (Leung et al. 2000).
The development of small molecular weight
inhibitors of MMPs offered the potential of
preventing tumor invasion and angiogenesis
thus inhibiting tumor growth and metastasis.
Interference with the activity of MMPs through
the expression of endogenous tissue inhibitors
of MMPs (TIMPS) has been shown to inhibit
invasion in vitro and in vivo and can block tumor-
induced neovacularization (Murphy et al. 1994).
The use of novel, non-classical anticancer agents
such as MMPs inhibitors represent a new and
potentially effective approach. AG3340
(Prinomastat) is targeted against MMP1 with
specificity directed against MMP2 and MMP-9
and this agent has been evaluated in two trials of
patients with stage IIIB and IV NSCLC (Shepherd
2001).
BAY 12-9566 (Tanomastat) is a MMPs
inhibitor that has pre-clinical activity in ovarian
cancer models. It is a novel and specific non –
peptidic biphenyl MMP inhibitor against several
MMPs implicated in tumor progression
(Rowinsky et al. 2000). BMS-275291, an orally
bio-available MMP inhibitor currently under
development, has been shown to decrease the
overall tumor burden in several animal models
(Poulaki 2002). It is the newest MMP1 to be
evaluated in lung cancer. It is broader spectrum
with activity against MMPs 1, 2, 8, 9, 13, 14 and
to some extent MMP3. MMP inhibitors (MMPI)
are primarily considered to have anti-proliferative
rather than direct cytotoxic effects. Neovastat
(AE-941) is a shark cartilage extract, which has
been shown to have MMP inhibitor activity
against MMP-2 and MMP-12. Clinical benefits
observed upon Neovastat treatment rely on the
presence of multiple angiogenesis inhibitors
including inhibitors of MMP activities (Gingras
et al. 2001).
Neovastat specifically stimulates tPA-
dependent plasmin generation through an
increase in the affinity of the enzyme towards
plasminogen apart from its stimulatory effect on
tPA activity, neovastat also markedly stimulates
tPA expression in endothelial cells through an
increase in the transcription of the tPA gene
(Gingras et al. 2004). Anginex is a potent inhibitor
of EC adhesion and migration and function by
apoptosis (Griffioen et al. 2001).
Marismastat is a broad- spectrum MMP
inhibitor. It is currently in phase III clinical trials
and is being evaluated for the treatment of
invasive cancers and metastasis (Summers and
Davidsen, 1998) (Fig. 3A). Recent advances in
development of tetracycline derivatives as
potential inhibitors of MMPs, which have shown
promising preclinical and early clinical results
(Acharya et al, 2004). BILA 2157BS is another
potent rennin inhibitor with some selectivity
towards cathepsin D (Simoneau et al. 1999). Brem
et al. (1990) found that a mild penicillamine-
induced copper deficiency greatly reduced the
growth of the tumors and their invasiveness. The
cyclic thiol MR889 has been investigated as a
chemotherapeutic agent for lung cancer (Inada
et al. 1997) (Fig. 3B). With its low toxicity and
good in vivo properties, it may soon enter human
trials. Bortezomib (PS-341), proteasome inhibitor,
(Fig. 3C) is the first inhibitor to undergo clinical
testing, has demonstrated impressive antitumor
activity and manageable toxicities in phase I and
II trials both as a single agent and in combination
with other drugs (Voorhees et al. 2003). Inhibitors
Fig. 3. Chemical structure of potent protease inhibitors implicated in antitumorigenesis:
A: Maristamat. B: MR889. C: Bortezomib (PS- 341).
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of the proteasome impact on cells, in part, through
down regulation of nuclear factor kB, but also
through modulation of cell cycle proteins and
other pro and anti apoptotic pathways. The
development of specific and potent chemical
inhibitors of the proteasome has sparked
considerable excitement about the therapeutic
potential of this class of drugs not only in cancer
but other immune disorders (Mitchell 2003). MG-
132, vinyl sulfone, epoxomicin, lactacystin and
clasto-lactacystin b-lactone are some of the
representative classes of proteasome inhibitors.
ADAM activities are regulated by a group of
physiological inhibitors called (TIMPs). TIMPs
have shown the inhibiting properties against the
protease activity of certain ADAM molecules.
TIMP-1 and TIMP-3 has been shown to inhibit
the protease activity of ADAM-10, while only
TIMP-3 has been demonstrated to be inhibitory
towards ADAM-17/TACE (Amour et al. 1998).
Genomics and Proteomics of Proteases in
Tumorigenesis
Cancer is a genetic disease caused by
changes or modification of DNA sequences of
key genes that result in altered gene or protein
expression or altered protein composition of
tumor cells. Genetic changes and environmental
factors interact to influence cancer development
(Rasooly and Jacobson 2006). It is now possible
with new genomic and proteomic technology
using single nucleotide polymorphism, proteo-
mics, epitomics and messenger ribonucleic acid
analysis, molecular approaches to early detection
and prognostic determination in prostate cancer
possible. Through out the world, technologies
in molecular diagnostics and prodiagnostics are
being developed that are enhancing our ability
to gain insight into molecular targeted agents
(Rashid 2006).
Genomic structural changes have been
deduced under certain pathological conditions
using a variety of methods such as Comparative
Genomic Hybridization (CGH), analysis for Loss
of Heterozygocity (LOH) and Fluorescence in
situ Hybridization (FISH). Several chromosomal
regions have been identified for their frequent
deletions in various types of cancer. Chromo-
somal deletion is an early and frequent somatic
genetic alteration during carcinogenesis. Gene
expression patterns resulting from regional
chromosomal events such as gene amplification,
deletion, rearrangement and epigenetic transcrip-
tional mechanisms are obscured in patterns
derived from remote loci. Hierarchical clustering,
K-means clustering, self-organizing maps and
support vector machines are some commonly
used methods in microarray data analysis (Yi,
2005). VEGF mRNA expression in lung cancer,
tyrosine kinases in leukemia and HER-2 receptors
in breast cancer are well-characterized targets.
All of theses targets have been identified in late
invasive and metastatic cancers, thereby limiting
the success of treatment. However, if targets in
the earliest stage of the tumor can be identified,
then treatment is likely to be more successful.
Recently, application of biomarkers in cancer
treatment has become increasingly target
oriented (Negm 2002).
Human tissue kallikreins, (hK3) also known
as prostate-specific antigens (PSA) is primarily
known their clinical applicability as cancer
biomarkers. These are secreted serine PRs and
are the latest arrival on the cancer proteolysis
scenario. Evidence indicates the importance of
kallikrein in many cancer related process,
including role in PRs activation cascades, cell
growth regulation, angiogenesis, invasion and
metastasis (Borgono and Diamandis, 2004). With
the improvement in proteomics technology, it is
now possible to adopt these technologies
directly in clinical diagnostic tests such as SELDI-
TOF mass spectrometry. A discriminatory
spectrum proteomics profiles could be generated
using this technology with a pattern recognition
based bioinformatics tool, that would help
distinguish men with prostrate cancer from those
with benign prostrates. This methodology will
improve the specificity and sensitivity of
prostrate cancer after technological difficulties
are overcome and refinements are made in this
technique (Ornstein 2006). Earlier, most
proteomics studies have used the tumor tissue
itself as the source for biomarker discovery but
with the advances in proteomics technologies
and the knowledge of the molecular milieu of even
localized cancer is reflected in circulating fluids.
From differential analysis for the identification
of biomarkers to functional analysis for the identi-
fication and/or validation of new therapeutic
targets, proteomics brings new comprehensive
information for a better understanding of the
molecular basis of oncology and new perspec-
tives for the clinic. However, the major limitation
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of post-genomic approaches remains the
molecular and cellular complexity of biological
systems. Traditionally, proteomics studies have
been used for biomarker discovery and the clinical
test is typically an enzyme-linked immunosorbent
assay (ELISA) based assay. Furthermore, with
the advent of high-throughput methods, it is
possible that some of these analytical instruments
will become usable for proteomic-based clinical
diagnostics.
This is in contrast to a common belief that
activity of PRs mostly has a negative influence
in cancer. With the discovery of efficient and
specific inhibitors, it was supposed to be an
efficient cancer treatment. Relatively benign
cancers acquire malignant properties when PRs
expression is up regulated. Highly malignant cells
become less aggressive when PRs expression or
activity is reduced. Many angiogenesis inhibitors
are stored as cryptic fragments within larger
precursor matrix molecules that are not
themselves antiangiogenic and the regulation of
proteolytic processing plays an important role in
the vascularization of tumors. It contributes more
to tumor progression and regulation than just by
degrading physical ECM barriers and enabling
cell migration and tumor invasion. They release
matrix-bound growth factors and endogenous
angiogenesis inhibitors, process anti-
inflammatory chemokine, expose cryptic integrin-
binding sites and affect cell-to-cell interactions
and apoptosis. Promoter methylation has been
well recognized as an important epigenetic
change in the development of cancer (Baylin and
Herman 2000).
Gene Expression Signatures in Cancer
Traditional methods of phenotypic
characterization are often limited and do not have
the ability to discern subtle differences that may
be of importance for developing a better
understanding of the tumor and advancing
therapeutic strategies for the treatment of disease.
A gene expression database contains the
expression profile of 218 tumor samples
representing 14 common human cancer classes.
Accurate multi class classification is now possible,
making molecular cancer diagnosis feasible by
means of comparisons with a comprehensive and
commonly accessible catalogue of genes
expression profile (Ramaswamy et al. 2001). A
variety of biochemical and molecular factors that
are reported to have prognostic or predictive
ability include cathepsin D, HER2, EGFR, p53,
UPA, PAI etc. Human squamous cell carcinomas
(SCC) are characterized by up-regulation of
MMP1, 10, 13 and cathepsin L2 (Haider et al.
2006). MMP-2 and MMP-9 have been shown to
be up regulated and that the two forms have a
significant role in many of the pathologic
conditions related to metastasized cancers
associated with tumor aggressiveness, metastatic
potential and poor prognosis (Johansson et al.
2000). TIMPs have been associated with less
aggressive and favorable prognosis in patients.
However, other studies have shown increased
expression of TIMPs, particularly TIMP-2, to
correlate with more aggressive tumor
development (Karameris et al.1997). Thus TIMPs
may have a dual effect on tumor growth and
metastasis and in addition to suppressing
proteolysis and neovascularization of MMP.
They also may promote tumor cell proliferation
during discrete stages of tumor development
(Henriet et al. 1999). Chemically modified
tetracyclines (CMTs) have also been shown to
down regulate expression of gelatinases and thus
to reduce the production of proenzyme. Also,
CMTs inhibit the activation of collagenase and
gelatinase pro enzyme form (Golub et al.1991).
Gene expression information generated by
DNA microarray analysis of human tumors can
provide molecular phenotyping that identifies
distinct tumor classifications not evident by
traditional histopathological methods. The
promise of such information lies in the potential
to inform and so improve clinical decisions and
strategies used to treat patients with neoplastic
disease (Alizadeh et al. 2000). The Ovarian Cancer
Prognostic Profile (OCPP), a 115-gene signature
is an independent prognostic determinant of
outcome in epithelial ovarian cancer (EOC). The
use of gene profiling may ultimately permit
identification of EOC patients appropriate for
investigational treatment approaches, based on
a low likelihood of achieving prolonged survival
with standard first line platinum based therapy
(Spentzos  et al. 2004).
Enzyme based histochemical analysis
showed that some leukemia’s were periodic acid-
Schiff positive, whereas others were myelopero-
xidase positive. This provides the first basis for
classification of acute leukemias into those arising
from lymphoid precursors (acute lymphoblastic
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myeloid leukemia, AML) (Golub et al.1999). The
use of expression profiling with cDNA array
techniques in mammary tumor cell lines and breast
tumors help in classifying controversial tumors
and provide new prognostic tools and potential
therapeutic targets (Bertucci et al. 2001).
Numerous studies have correlated genetic
alterations with clinical outcome including a
strong correlation between the amplification of
the erbB-2 receptor gene (Her-2) and poor clinical
outcome (Ciocca et al. 1992). Also over expression
of erbB-2 is a strong predictor of response to
adriamycin- based therapy (Muss et al. 1994).
The analysis of gene expression represents an
indirect measure of the genetic alterations in
tumor because these alterations affect gene
regulatory pathways. The analysis of gene
expression represents an indirect measure of the
genetic alterations in tumors because in most
instances these alterations affect gene regulatory
pathways. The tremendous complexities that can
be scored by measuring gene expression with
DNA microarrays together with the absence of
bias in assumptions as to what type of pathway
might be affected in a particular tumor, the analysis
of gene expression profile offers the potential to
impact clinical decision-making based on more
precise determination of tumor cell phenotypes
(West et al. 2001).
Although cancer classification has improved
over last 30 years, there has been no general
approach for identifying new cancer classes
(class discovery) or for assigning tumors to
known classes (class prediction). The feasibility
of its classification based solely on gene
expression monitoring and suggests a general
strategy for discovering and predicting cancer
classes for other types of cancer, independent of
previous biological knowledge. Improvements in
cancer classification have thus been central to
advances in cancer treatment. Tumors with
similar histopathological appearance can follow
significantly different clinical courses and show
different responses to therapy (Golub et al.1999).
Classification of leukemias and lymphomas
that have been achieved in recent year’s analysis
of gene expression patterns represent significant
steps in the development of methodologies to
phenotype tumors (Golub et al. 1999). Bayesian
regression models that provide predictive
capability based on gene expression data derived
from DNA microarray analysis of a series of
primary breast cancer samples, have the capacity
to discriminate breast tumors on the basis of
estrogen receptor status and also on the
categorized lymph node status (West et al. 2001).
Using the gene expression profiling patterns
patients were classified into two groups namely,
the St. Gallen criteria and National Institute of
health (NIH) consensus criteria. The St. Gallen
and NIH criteria classify patients as at low risk or
high risk on the basis of various histological and
clinical characteristics. This comparison shows
that the prognosis profile assigned many more
patients with lymph node-negative diseases to
the low risk (good–prognosis signature) group
than did the traditional methods (Van de Vijver et
al. 2002). The primary breast tumors were
classified as having either a poor prognosis
signature,which means they were likely to
metastasize,or a good –prognosis signature,
meaning that the development of metastasize was
unlikely. The classification of patients in to high
risk and low risk subgroup on the basis of the
prognosis profile may be a useful means of
guiding adjuvant therapy in patients with lymph
node- positive breast cancer. This approach also
improves the selection of patients who would
benefit from adjuvant systemic treatment,
reducing the rate of both over treatment and under
treatment. Other methods of classification are
based on OVA SVM-based and S2N classifier.
Perou et al. (1999) identified tumors with
distinct patterns of gene expression that they
termed basal and luminal type. Microarray
analysis has been used to distinguish cancers
associated with BRCA1 or BRCA2 mutations
(vant’s Veer et al. 2002) to determine estrogen-
receptor status (Gruvberger et al. 2001) and lymph
node status (Ahr et al. 2002). Fulvestrant is the
pure estrogen antagonist, which help in
degradation of estrogen receptor a. It works by
enhancing proteasome-dependent degradation
of the client protein via ubiquituin-proteasome
pathway. It is approved for use by postmeno-
pausal patient with estrogen receptor positive
breast cancer who has progressed following other
anti-estrogen therapy (Orlowski and Claire Dees
2002). The three-gene expression predictive of
subsequent relapse status comprised genes
involved in cell cycle control (CCNE1), DNA
methylation (DNMT3B) and DNA damage repair
(BRCA2). This gene expression signature is an
introductory candidate for routine clinical use,
especially as the three genes encode well
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bodies are already available (Bieche et al. 2004).
hk8 is the favorable prognostic marker in ovarian
cancer (Borgono et al. 2006).PAI an uPA are
independent prognostic markers  in breast
cancer.Apart from the lymph node status,high
levels of uPA and PAI 1 are the strongest
prognostic markers for disease free survival and
overall survival. Patients with lymph node –
negative tumors the levels of uPA and PAI1 are
the strongest predictor of metastasis.In addition,
the two markers might also be used to predict
response therapy in particular the response to
adjuvant therapy (Weigelt et al. 2005).
ONCOMINE is a database that connects the
cancer microarray database to several sources
of additional information, including the scientific
literature, the human protein reference database
and online catalog of all proven disease-gene
connections.
Drug Design and Development
Numerous practical applications in the area of
cancer research and the understanding that PRs
are important targets for the drug design,
ultimately fuelled much research in this field.
Specific PRs inhibitors, likely in combination with
conventional anticancer agent will probably prove
to have value for certain forms of cancer. The
substrates identified for PRs provide a “signature”
set of peptides that can be used to identify the
activity of theses PRs in blood. These substrates
can be incorporated into diagnostic assays, or
into imaging agents to image the position of distant
metastasis, or to monitor disease progression. In
addition, the substrate phage technology can be
pushed to a level that is likely to help reveal the
substrate recognition specificity of all PRs in
human genome. This technology can also be used
to develop PRs profile signatures for all types of
cancers (Kridel et al. 2001).
Differences in the sub-site structure of human
cathepsin D and related human aspartic
proteases may be exploited for drug design
(Baldwin et al.1993). It is now becoming obvious
that cysteines and cathepsins should be
seriously considered as potential target in cancer
treatment. Serine PRs TAT-2 (Tumor associated
trypsinogen) might be a good candidate for a
clinical prognostic marker that could identify
patients with an aggressive disease (Nyberg et
al. 2006). XIAP, an endogenous inhibitor of
caspases (another family of cysteinyl PRs), could
be an attractive target for cancer drug develop-
ment, since caspase 3 derepression leads to
apoptosis and/or sensitization of tumor cells for
chemotherapeutic drugs (Schimmer et al. 2004).
Among all pharmacological targets, inhibition
of function of MMPs in ECM after secretion is
being most actively pursued as a potential
anticancer strategy. Once secreted into the ECM,
activation of pro MMP could be inhibited or
enzymatic activity could also be directly inhibited
(Hindalgo and Echardt 2001). Matrilysin (MMP7)
has been the point of attention because of its
preferential expression in early stages tumors and
pre-malignant lesions, which make it suitable
target for chemo-preventive strategies (Wilson
et al. 1997). However, the failure of broad-
spectrum MMP inhibitions in clinical trials has
opened the door for other PRs to be considered
as relevant drug targets in anti cancer therapy.
The compound JPM-OEt had profound effects
on tumor growth, invasiveness and angiogenic
switching, disrupting both early and late stages
of tumorigenesis in contrast to MMP inhibitors,
which have not proved effective in the later stages
of tumorigenesis. A number of PRs, such as
proteaosome histone deacetylase are emerging
as potential drug targets in cancer and now new
selective inhibitors of MMPs are being
developed (Coussens 2002).
Measuring the “recognition-specificity” for
a large number of PRs at one time using a powerful
biochemical technique called substrate phage
display, millions of different peptide structures
(called library) can be displayed on a common
scaffold. This library of substrates when exposed
to individual PRs, few peptides that are cleaved
by the PRs could be identified. Using this strategy
unique recognition for three PRs associated with
breast cancer, MMP-2, 9, along with membrane
type-1 MMPs. Each of theses enzymes are
involved in tumor invasion, tumor metastasis and
perhaps more significantly with tumor
angiogenesis. The substrate- based drug design
has been substantially improved in recent years
the availability of three-dimensional structure
information for peptidases, permit receptor based
design. The structural information about the
active site of the receptor or (peptidase) and
selection of designed molecules with the aid of
computers has helped to design receptor-based
inhibitors. Combinatorial chemistry also presents
opportunities both to discover new molecular
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tures for the development of peptidase inhibitors
(Leung et al. 2000). A new class of peptidomi-
metics, the unsymmetrical peptidyl ureas, have
emerged as powerful inhibitors of aspartic pepti-
dase (Dales et al. 2001). These were developed
using mechanism- based and substrate- based
design techniques and using the computational
method GrowMol (Ripka et al. 2001).
In vitro and in vivo studies have shown that
PRs inhibitors reduce tumorigenicity. The wide
expanse of knowledge gained so far still leaves
several key questions unanswered. Analysis of
multiple PRs in a single model system would
further enhance the elucidation of the function
of PRs both in normal physiological conditions
and in tumor environment. This will help in the
design of better PRs based drugs and inhibitors
to combat malignancy (Griffioen et al. 2001).
The ubiquitin-proteasome pathway is just
beginning to be exploited as a target for cancer
therapy. Bortezomib, most notable proteasome
inhibitor is currently being evaluated in clinical
trials and has already been found to have
significant antitumor efficacy. Its primary action
involves modulation of proteasome-ubiquitin
activity. Geldanamycin, camptothecins, irino-
tecan and fulvestrant are some of the drugs that
act by increasing ubiquitin-proteasome pathway-
mediated degradation of a target protein
(Orlowski and Claire Dees 2002).
Several kallikreins are differentially expressed
at both mRNA and protein levels in various
endocrine–related malignancies and have
prognostic value. In addition to their diagnostic/
prognostic potential, kallikreins may also emerge
as attractive targets for therapeutics (Diamandis
and Yousef 2002). Today, the design of PRs
inhibitors involves a powerful combination of all
these traditional drug discovery approaches,
supplemented by de novo drug design,
combinatorial chemistry and phage display
techniques and supported by rapid robotic assay
methods to find or optimize inhibitor leads from
vast chemical libraries. The next decade will see
identification of many new PRs as targets for
inhibitor development following the advance-
ments made in the areas of molecular and cellular
biology, protein chemistry, microbiology,
structural biology, nano biotechnology and
molecular pharmacology. The complex roles of
PRs in different stages of tumor growth should
be kept in mind when designing PRs inhibitors
as cancer treatment (Nyberg 2006).
SCOPE  OF  THE  REVIEW  AND  FUTURE
PROSPECTS
Proteases have been widely studied for their
role in tumor growth, invasion and metastasis.
However, we still not have answered key
questions relating to the use of PRs inhibitors
for therapeutic interventions. Collaborations like
the PRs consortium that analyses multiple PRs
in a single tumor would further our knowledge of
how PRs are involved in tumor progression as
well as help us to design better inhibitors and
novel PRs based drugs for clinical use.The
European Cancer Proteases Consortium (EUCPC)
proposes multidisciplinary research into
innovative approach to cancer therapy and
diagnosis based on DEGRADOME. It is complete
repertoire of extracellular proteases through which
cells regulate their local environment. Extracellular
protease remains an attractive target for interven-
tion as for cancer, even if first generation anti –
protease drugs were disappointing. PRs inhibitor
discovery began with natural product screening
and substrate- derived analogue- based drug
design and then progressed with incorporation
of mechanism-based drug design strategies and
more recently has advanced further using
computer assisted structure-based inhibitor
design using three dimensional structures of PRs
determined by X-ray crystallography and NMR
spectroscopy.
Some of the questions still to be answered is
whether one PR or one class of PRs are more
important in specific tumor and at specific steps
in tumor progression than another, whether
extracellular PRs co-operatively influence matrix
degradation and tumor cell invasion through
proteolytic cascade, or do individuals PRs have
distinct influences on tumor growth, invasion,
migration and angiogenesis, whether proteolytic
cascade is important, can an upstream PRs be
targeted so only one PRs inhibitor is needed and
finally whether selective inhibitors be able to
decrease tumor growth and metastasis, possibly
decreasing the side effects  from broad host
spectrum PRs inhibitors. In this regard, hks,
proteasomes and ADAMs are the three
upcoming groups of proteases, which require
special attention. In view of the above mentioned
proteases, their respective inhibitors, aprotinin,
bortezomib (PS-341), TIMP-3 (inhibitor of
ADAM-17/TACE demand equal thrust and are
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regime. On the basis of findings, it is now
established that a few kallikreins have already
found important clinical applications, whereas
other members show promising potential.
ADAMs is a relatively recent discovery.
Therefore, studies on theses molecules in tumor
cells require further elucidation. In spite of their
potential roles in cancer metastasis through
metalloproteases and disintegrin domains, the
expression studies and hormonal regulation of
ADAMs is poorly documented in cancer cell
types. Mature phase II data evaluating borte-
zomib in combination with other agents for solid
tumors and trials evaluating its role earlier in
multiple myeloma therapy, are eagerly awaited as
efficacy of bortezomib in solid tumors are less
mature. Researches at the University of
Michigan, Johns Hopkins and the Institute of
Bioinformatics in India have discovered a gene
expression signature common to distinct types
of cancer, thus giving new dimensions to the
diagnostic and prognostic methods by develop-
ing a universal treatment for the world’s second
most dreaded disease. This is a unique approach
in a sense that all earlier approaches invariably
focused on the differences in the gene expression
pattern of different types of carcinomas. On the
basis of illustrations in this review, it does not
take much speculation to understand that PRs
inhibitors will increasingly become valuable
molecular probe for improving our understanding
of biological processes as well as commercially
valuable drug candidate for treating cancer.
The review will be incomplete without the
mention of nano-biotechnology, which is one of
the upcoming fields of science in the treatment
of cancer. It offers us an unprecedented and
paradigm-changing opportunity by offering a
wealth of tools, such as new and innovative ways
to diagnose and treat cancer. Quantum dots,
nanopores, and other devices for detection and
treatment may be available for clinical use in 5-10
years. The greatest advantage of the nano-
biotechnology would be in potentially
developing ways to irradiate cancer cells without
harming healthy neighboring cells in addition to
its role in the early, minimally invasive method of
detection of cancer cells. Though nano-
biotechnology is a promising approach in the
treatment of cancer, certain legal and ethical
issues need to be addressed.
Gene expression profiling by DNA micro-
arrays can be used to accurately diagnose and
molecularly classify tumors, assess their
propensity to metastasize and predict responses
to combination therapy. Therefore, there is keen
interest in defining the gene expression of all
human tumors to create a new generation of
clinically useful cancer diagnosis. DNA microarray
technology is easy to use, yield gene expression
measurements for thousands of genes simulta-
neously. This has made possible the prediction
of the metastatic potential of a tumor, which
requires the analysis of many different markers
at once by analyzing gene expression in a genome
wide fashion (microarray-plateform). Aggregate
patterns of gene expression (metagenes) are
associated with lymph-node status at diagnosis
and a 3 year-recurrence risk in breast cancer
patients of all ages. Further studies are required
to validate metagene classifier for breast cancer
recurrence. Gene expression signatures might
refine the prognostic classification of cancer
allowing researchers to move accurately in
identifying patients with metastatic risk than the
present conventional prognostic markers. The
genes that are deregulated, in the molecularly
defined classes with poor prognosis, might also
constitute novel targets for therapy.
Recently, tumor transcriptome revealed the
predictive and prognostic impact of lysosomal
protease inhibitors in NSCLC. This provides the
first comprehensive molecular characterization
of clinical responsiveness to platinum based
chemotherapy (PBC) in NSCLC, potentially repre-
senting novel targets for NSCLC therapeutics.
ACKNOWLEDGEMENTS
The Post Doctoral Fellowship from the
Department of Biotechnology (DBT), India is
gratefully acknowledged by Pandey R.
REFERENCES
Acharya R, Venitz J, Figg D, Sparreboom A 2004.
Chemically modified tetracyclines as inhibitors of
matrix Metalloproteinases. Drug Resistance
Updates, 7: 195–208.
Ahr A, Karn T, Solbach C, et al. 2002. Identification of
high risk breast cancer patients by gene expression
profiling. Lancet, 359: 131-132.
Alizadeh AA, Eisen MB, Davis RE, et al. 2000. Distinct
types of diffuse large B cell lymphoma identified by
gene expression profiling. Nature London, 403: 503-
511.
Amour A, Slocombe PM, Webster A, Butler M, Knight
CG, et al. 1998. TNF-alpha converting enzymePROTEASES AND PROTEASE INHIBITORS 79
(TACE) is inhibited by TIMP-3.FEBS Letters, 435:
39-44.
Aoki T,Takasaki T, Furukawa T, Morikawa J, Yaro
T,Watabe H 1995. Conversion of cathepsin E to
enzymatic unstable form in gastric cancer cells.
Biopharm Bull, 18: 1522-1525.
Azuma T,Yamada M, Murakita H, Nishikawa Y, Kohli
Y, Yamamoto K, Hori H 1995. Cathepsin E
expressed in pancreatic cancer. Adv Exp Med Biol,
362:363-366.
Baldwin ET, Bhat TN, Gulnik S, Hosur MV, Sowder RC
2nd, Cachau RE, Collins J, Silva AM, Erickson JW
1993. Crystal structures of native and inhibited
forms of human cathepsin D : Implications for
lysosomal and targeting and drug design. Proc Natl
Acad Sci USA, 90: 6796-6800.
Basset P, Wolf C, Champon P 1993. Expression of the
stromelysin gene in fibroblastic cells of invasive
carcinoma of the breast and other human tissues: a
review. Breast Cancer Res Treat, 24: 185-193.
Baylin SB, Herman JG 2000. DNA hypermethylation in
tumorigenesis: epigenetics joins genetics. Trends
Genet, 16: 168-174.
Bennett B, Babu-Khan S, Loeloff R, Louis J, Curran E,
Citron M, Vassar R 2000. Expression analysis of
BACE2 in brain and peripheral tissues. J Biol Chem,
275: 20647-20651.
Bernstein LR, Liotta LA 1994. Molecular mediators of
interactions with extracellular matrix components
in metastasis and angiogenesis. Curr Opin Oncol,
6: 106-113.
Bertucci F, Loriod B, Tagett R, Granjeaud S, Birnbaum
D, Nguyen C, Houlgatte R 2001. DNA arrays:
technological aspects and applications. Bull Cancer,
88: 243-252.
Bieche I, Tozlu S, Girault I, Lidereau R. 2004.
Identification of a three –gene expression signature
of poor – prognosis breast carcinoma. Molecular
Cancer,3: 37
Blanco-Aparicio C, Molina MA, Fernendes SE, Frazier
ML, et al. 1998. Potato carboxypeptidase inhibitor,
a T-knot protein, is an epidermal growth factor
antagonist that inhibits tumor cell growth. J Biol
Chem, 273: 12370-12377.
Borgono CA, Diamandis EP 2004. The emerging roles
of Human tissue kallikreins in cancer. Nat Rev
Cancer, 4: 876-890.
Borgoño CA., Kishi T, Scorilas A, Harbeck N, Dorn J,
Schmalfeldt B, Schmitt M, Diamandis EP 2006.
Human Kallikrein 8 Protein Is a Favorable
Prognostic Marker in Ovarian Cancer. Clin. Cancer
Res, 12: 1487-1493.
Brem SS et al.1990. Inhibition of angiogenesis and tumor
growth in the brain. Suppression of endothelial cell
turn over by penicillamine and the depletion of
copper, an angiogenic cofactor. Am J Pathol, 137:
1121-1142.
Brown PD, Giavazzi R 1995. Matrix metalloproteinase
inhibition: a review of antitumor activity. Annal
Oncol, 6: 967-974.
Campo E, Munoz J, Miquel, R et al. 1994. Cathepsin B
expression in colorectal carcinomas correlates with
tumor progression and shortened patient survival.
Am J Pathol, 145: 301-309.
Cawston T 1995. Proteinase and inhibitors. Br Med J,
51: 385-401.
Christeller JT, Farley PC, Ramsay RJ, Sullivan PA, Laing
WA 1998. Purification, characterization and cloning
of an aspartic proteinase inhibitor from squash
phloem exudates. Eur J Biochem, 254: 160-167.
Ciocca DR, Fujimura FK, Tandon AK, Clark GM, Mark
C, et al. 1992. Correlation of HER-2/neu
amplification with expression and with other
prognostic factors in 1103 breast cancers. J Natl
Cancer Inst, 84: 1279-1282.
Coussens LM, Fingleton B, Matrisian LM 2002. Matrix
metallproteinase inhibitors and cancer: trials and
tribulations. Science, 295: 2387-2392.
Curran S and Murray GI 1999. Matrix metalloproteinases
in tumor invasion and metastasis. J Pathol, 189:
300-308.
Dales N, Bohacek R, Satyshurk, Rich D 2001. Design
and synthesis of unsymmetrical peptidyl urea
inhibitors of asapartic peptidases. Org Lett, 3: 2313-
2316.
De Clerck YA, Shimada H, Taylor SM 1994.  Matrix
metalloproteinases and their inhibitors in tumor
progression. Ann NY Acad Sci, 732: 222-232.
Diamandis EP and Yousef GM 2002. Human tissue
kallikreins: A family of new cancer biomarker. Clin
Chem, 48: 1198-1205.
Egeblad M, Werb Z 2002. New functions for the matrix
metalloproteinases in cancer progression. Nat Rev
Cancer, 2: 161-174.
Fernandes AO, Banerji AP 1997. Long term feeding of
field bean protein containing protease inhibitors
suppress virus- induced mammary tumors in mice.
Cancer Lett, 116: 1-7.
   Fidler IJ 1990. Critical factors in the biology of human
cancer metastasis: Twenty eight GHA Clowes
Memorial Award Lecture. Cancer Res, 50: 6130-
6138.
Gingras D, Labelle D, Nyalendo C, Biovin D, Demeule
M, Barthomeuf C, Beliveau R 2004. The
antiangiogenic agent Neovastat (AE-941) stimulates
tissue plasminogen activator activity. Invest New
Drugs, 22: 17-26.
Gingras D, Renaud A, Mousseau N, Beaulieu E, Kachra Z,
Beliveau R 2001. Matrix proteinase inhibition by
AE-941, a multifunctional antiangiogenic compound.
Anticancer Res, 21: 145-155.
Goetzl EJ, Banda MJ, Leppert D 1996. Commentary:
Matrix metalloproteinases in immunity. J Immunol,
156: 1-4.
Golub LM, Ramamurthy NS, McNamara TF, Greenwald
RA, Rifkin BR 1991. Tetracyclines inhibit
connective tissue breakdown: new therapeutic
implications for an old family of drugs. Crit Rev
Oral Biol Med, 2: 297-321.
Golub TR, Slonim DK, Tamayo P, Huard C, Gassenbeek
M, et al. 1999. Molecular Classification of Cancer:
Class Discovery and Class Prediction by Gene
Expression Monitoring. Science, 286: 531-537.
Griffioen AW, van der Schaft DW, Barendsz-Janson AF,
Cox A, Struijker Boudier HA, et al. 2001. Anginex,
a designed peptide that inhibits angiogenesis.
Biochem J, 354: 233–242.
Gruvberger S, Ringner M, Chen Y, et al. 2001. Estrogen
receptor status in breast cancer is associated withRACHNA PANDEY, NITIN PATIL AND MALA RAO 80
remarkably distinct gene expression pattern. Cancer
Res, 61: 5979-5984.
Haider AS, Peters SB, Kaporis H, Cardinale I, FeiJi, Ott
J, Blumenberg M, Bowcock AM, Krueger JG, Carruci
JA. 2006. Genomic analysis defines a cancer specific
gene expression signature for human squamous cell
carcinoma and distinguishes malignant hyper-
proliferation from benign hyperplasia. J Invest
Dermat, 126: 869-881
Henriet P, Blavier L, DeClerk YA 1999. Tissue inhibitors
of metalloproteinase (TIMP) in invasion and
proliferation. APMIS, 107: 111-119.
Hewitt RE, Leach IH, Powe DG, Clark IM, Cawston TE,
Turner DR 1991. Distribution of collagenase and
tissue inhibitor of metalloproteinases (TIMP) in
colorectal tumors. Int J Cancer, 49: 666-672.
Hindalgo M, Echardt GS 2001. Development of matrix
metalloproteinase inhibitors in cancer therapy. J
Natl Cancer Inst, 93: 178-193.
Huovila A-PJ, Turner AJ, Pelto-Huikko M, Karkkainen
I, Ortiz RM 2005. Shedding light on ADAMs
metalloproteases. Trends Biochem Sci, 30: 413-
422.
Inada M, Yamashita J, Ogawa M 1997. Neutrophil
elastase inhibitor (ONO-5046-Na) inhibits the
growth of human lung cancer cell lines transplanted
into severe combined immunodeficiency (scid) mice.
Res Commun Mol Pathol Pharmacol, 97: 229-232.
Johansson N, Ahonen M, Kahari VM 2000. Matrix
metalloproteinase in tumor invasion. Cell Mol Life
Sci, 57: 5-15.
Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo
E, et. al. 2004. Cathepsin cysteine proteases are
effectors of invasive growth and angiogenesis during
multistage tumorigenesis. Cancer Cell, 5: 409-410.
Kageyama T 1998. Molecular cloning, expression and
characterization of an Ascaris inhibitor for pepsin
and Cathepsin E. Eur J Biochem, 253: 804-809.
Karameris A, Panagou P, Tsilalis T, Bouros D 1997.
Association of expression of metalloproteinase and
their inhibitors with the metastasitc potential of
metalloproteinases and their inhibitors with the
metastatic potential of squamous lung carcinoma.
Am J Respir Crit Care Med, 156: 1930-1936.
Karan D, Lin FC, Bryan M, Ringel J, Moniaux N, Lin
Ming-Fong, Batra SK 2003. Expression of ADAMs
(a distintegrin and metalloproteases) and TIMP-3
(tissue inhibitor of metalloproteinase-3) in human
prostatic adenocarcinomas. Int J Oncol,  23: 1365-
1371.
KatoY, NagashimaY, Koshikawa N, Miyagi Y, Yasumitsu
H, Miyazaki K 1998. Production of trypsins by human
gastric cancer cells correlates with their malignant
phenotype. Eur J  Cancer, 34: 1117-1123.
Koblinski JE, Mamoun A, Sloane BF 2000.Unraveling
the role of proteases in cancer. Clinica Chimica
Acta, 291: 113-135.
Koivunen E, Itkonen O, Halila H, Stenman UH 1990.
Cyst fluid of ovarian cancer patients contains high
concentrations of trypsinogen-2. Cancer Res, 50:
2375-2378.
Kridel SJ, Chen E, Kotra LP, Howard EW, Mobashery S,
Smith JW 2001. A substrate phage enzyme- linked
immunoabsorbant assay to profile panels of
proteases. Anal Biochem, 294: 176-184.
Lenarcic B, Turk V 1999. Thyroglobulin Type-1 domains
in equistatin inhibit both papain –like cystein
proteinases and cathepsin D. J Biol Chem, 274:
563-566.
Leung D, Abbenante G, Fairlie DP 2000. Protease
inhibitors: Current status and future prospects. J
Med Chem, 43: 305-340.
Liotta LA, Rao CN, Barsky SH 1983. Tumor invasion
and the extracellular matrix. Lab Invest, 49: 636-
49.
      Luisetti M, Sturani C, Sella D, Madonini E, Galavotti
V, Bruno G, Peona V, Kucich U, Dagnino G,
Rosenbloom J, Starcher B, Grassi C 1996. MR889,
a neutrophil elastase inhibitor, in patients with
chronic obstructive pulmonary disease: a double-
blind, randomized, placebo-controlled clinical trial.
Eur Respir J,  9: 1482-86.
Masson R, Lefebvre O, Noel A, Fahime ME, Chenard
MP, et al. 1998. In vivo evidence that the
stromelysin-3 metalloproteinase contributes in a
paracrine manner to epithelial cell malignancy. J
Cell Biol, 140: 1535-1541.
Mignatti P, Rifkin DB 1993. Biology and biochemistry
pf proteinases in tumor invasion. Physiol Rev, 73:
161-195.
Mitchell BS 2003. The proteasome-an emerging
therapeutic target in cancer. NEJM    Perspective,
348: 2597-2598.
Murphy G, Willenbrock F, Crabbe T, et al. 1994.
Regulation of matrix metalloproteinase activity.
Ann NY Acad Aci, 732: 31-40.
Muss HB, Thor AD, Berry DA, Kute T, Liu ET, et al.
1994. c-erbB-2 expression and response to adjuvant
therapy in women with node-positive early breast
cancer. N Engl J Med, 331: 211.
Navab R, Mort JS, Brodt P 1997. Inhibition of carcinoma
cell invasion and liver metastases formation by the
cystein proteinase inhibitor E-64. Clin Exp
Metastasis, 15: 121-129.
Negm RS, Verma M, Srivastava S 2002. The promise of
biomarkers in cancer screening and detection.
TRENDS Mol Med, 8: 288293.
Netzl-Arnett S, Hooper JD, Szabo R, Madison L, Quigley
JP, Bugge TH, Antalis TM 2003. Membrane
anchored serine proteases: a rapidly expanding
groups of cell surface proteolytic enzymes with
potential roles in cancer. Cancer Metastasis Rev,
22: 22237-258.
Ng KKS, Peterson J, Cherny M, Garen C, Zalatoris J,
Rao-Naik C, Dunn B, Martzen M, Peanasky R,
James M 2000. Structural basis for the inhibition of
porcine pepsin by Ascaris pepsin inhibitor-3. Nat
Struct Biol, 7: 653-657.
Noel A, Fontes R, Emonard H, Foidart JM 1993.
Extensive deposition of basement membrane by
tumors: a prognostic factor? A reappraisal. Epithelial
Cell Biol, 2: 150-154.
Nyberg P, Ylipalosaari M, Sorsa T, Salo T 2006. Trypsin
and their role in carcinoma growth. Exp Cell Res,
312: 1219-1228.
Orlowski RZ, Claire DE 2003. The role of the
ubiquitination-proteasome pathway in breast
cancer: Applying drugs that affect the ubiquitin-
proteasome pathway of breast cancer. Breast Cancer
Res. 5: 1-7.PROTEASES AND PROTEASE INHIBITORS 81
Ornstein DK, Tyson DR 2006. Proteomics for the
identification of new prostate cancer biomarkers.
Urology and Oncology: Seminars and original
Investigations, 24: 231-236.
Page AE, Warburton MJ, Chambers TJ, Pringle JA,
Haymann AR 1992. Human  osteoclastomas contain
multiple forms of cathepsin B. Biochem Biophy
Acta, 1116: 57-66.
Pajonk F, McBride WH. 2001. The proteasome in cancer
biology and treatment. Radiat Res, 156: 447-59.
Perou CM, Jeffery SS, van deRijn M,  Rees CA, Eisen
MB, et al. 1999. Distinctive gene expression
patterns in human mammary epithelial cells and
breast cancers. Proc Natl Acad Sci USA, 96: 9212-
9217.
Polyak K, Riggins GJ 2001. Gene discovery using the
serial analysis of gene expression technique:
implications for cancer research. J Clin Oncol, 19:
2948-2958.
Poole  AR, Tiltman KJ, Recklies AD, Stoker TAM 1978.
Differences in secretion of the proteinases cathepsin
B at the edges of human breast carcinomas and
fibroadenomas. Nature, 273: 545-547.
Poulaki V 2002. BMS-275291 Bristol- Meyers Squibb.
Curr Opin Invest Drugs, 3: 500-504.
Puente XS, Sanchez LM, Overall CM, Lopez-Otin C
2003. Human and Mouse Proteases: A Comparative
Genomic Approach. Nat Rev Genet, 4: 544-558.
Ramaswamy S, Osteen RT, Shulman LN 2001. Metastatic
cancer from an unknown primary site. In: RE
Lenhard, RT Osteen, T.Gasler (Eds.): Clinical
Oncology, Atlanta: American Cancer Society pp.
711-719.
Ramaswamy S, Perou CM 2003. DNA microarrays in
breast cancer: the promise of personalised medicine.
The Lancet, 361: 1576-1577.
Rashid HH, Koeneman KS 2006. Prostate cancer:
Molecular approaches for detection and prognosis
and angiogenic therapeutic targets. Urologic
Oncology: Seminars and Original Investigations,
24: 220-221.
Rasooly A, Jacobson J 2006. Development of cancer
clinical testing. Biosens Bioelectron, 21: 1851-1858.
Ray JM, Stetler-Stevenson W 1994. The role of matrix
metalloproteinases and their inhibitors in tumor
invasion, metastaisis and angiogenesis. Eur Resir J,
7: 2060-2072.
Rempel SA, Rosenblum ML, Mikkelson T et al. 1994.
Cathepsin B expression and localization in glioma
progression and invasion. Cancer Res, 54: 6027-
6031.
Ripka A, Satyshur K, Bohacek R, Rich D 2001. Aspartic
protease inhibitors designed from computer-
generated templates bind as predicted. Organic
Letters, 3: 2309-2312.
Rowinsky E, Humphrey R, Hamod LA et al. 2000. Phase
I and pharmacologic study of the specific matrix
metalloproteinase inhibitor BAY 12- 9566 on a
protracted oral daily dosing schedule in patients
with solid malignancies. J Clin Oncol, 18: 178-
186.
Rozhin J, Sameni M, Ziegler G, Sloane BF 1994.
Pericellular pH affects distribution and secretion of
cathepsin B in malignant cells. Cancer Res, 54:
6517-6525.
Schimmer AD, Welsh K, Pinilla C, Wang Z, Krajewaska
M, et al. 2004. Small-molecule antagonists of
apoptosis suppressor XIAP exhibit broad antitumor
activity. Cancer Cell, 5: 25-35.
Shepherd FA 2001. Angiogenesis inhibitors in the
treatment of lung cancer. Lung Cancer, 34: S81–
S89.
Simoneau B, Lavallee P, Anderson PC et al. 1999.
Discovery of non-peptidic P2-P3 butanediamide
rennin inhibitors with high oral efficacy. Bioorg
Med Chem, 7: 489-508.
Sinha AA, Wilson MJ, Gleson DF, Reddy PK, Sameni M,
Sloane BF 1995. immunohistochemical localization
of cathepsin B in neoplastic human prostrate.
Prostrate, 26: 171-178.
Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu
Xuesong, Boyd J, Liberman TA, Cannistra SA 2004.
Gene expression signature with independent
prognostic significance in epithelial ovarian cancer.
J Clin Oncol, 23: 4700-4710.
Sukoh N, Abe S, Ogura S et al. 1994. Immunohisto-
chemical study of cathepsin B.; prognostic
significance in human lung cancer. Cancer, 74: 46-
51.
Summers JB, Davidsen SK 1998. Matrix metallopro-
teinase inhibitors and cancer. In: JA Bristol  (Ed.):
Annual Reports in Medicinal Chemistry. Michigan:
Academic Press. l33: 131-134.
Sympson CJ, Bissell  MJ, Werb Z 1995. Mammary gland
tumor formation in transgenic mice overexpressing
stromelysin-1. Semin Cancer Biol, 6: 159-163.
Taipale J, Keski-Oja J 1997. Growth factors in the
extracellular matrix. FASEB J, 11: 51-59.
Tolcher AW, Kennedy AR, Padley RJ, Majeed N, Pollak
M, Kantoff PW 2001. Other novel agents: rationale
and current status as chemopreventive agents.
Urology, 57: 86-89.
Umezawa H, Ayogi T, Morishima H, Matsuzaki M,
Hanada M, Takeuchi T 1970. Pepstatin. A new
pepsin inhibitor produced by Actinomycetes. J
Antibiot, 23: 259-262.
Van de Vijver MJ,  He YD, van ‘t Veer LJ, Dai H, et al.
2002. A Gene-Expression Signature as a Predictor
of Survival in Breast Cancer. N Eng J Med, 347:
1999-2009.
vant’s Veer LJ, dai H, van de Vijver MJ 2002. Gene
expression profiling predicts clinical outcome of
breast cancer. Nature, 415: 530-536.
Verstraete M 1985. Clinical applications of inhibitors in
fibrinolysis. Drug, 29: 236-261.
Vicari AP, Caux C 2002. Chemokines in cancer. Cytokine
Growth Factor Rev, 13: 143-154.
Visse R, Nagase H 2003. Matrix metalloproteinases and
tissue inhibitors of metalloproteinases: structure,
function and biochemistry. Circ Res, 92: 827-839.
Voorhees PM, Calire dees, O’Neil B, Orlowski RZ 2003.
The proteasome as a target for cancer therapy.
Clinical Cancer Res, 9: 6316-6325
Watanabe M, Higashi J, Watanabe A, Osawa T, Sato Y, et
al. 1989. Cathepsin B and L activities in gastric
cancer tissue correlates with histological findings.
Biochem Med Metab Biol, 42: 21-29.
Weigelt B, Peterse LJ, Van’t Veer L. 2005.  Breast cancer
metastasis: Markers and models. Nat Rev Cancer,
5: 591-602.RACHNA PANDEY, NITIN PATIL AND MALA RAO 82
West M, Blanchette C, Dressman H, Huang E, Ishida S,
et al. 2001 Predicting the clinical status of human
breast cancer by using gene expression profiles. Proc
Natl Acad Sci USA, 98: 11462-11467.
Whitelock JM, Murdock AD, Iozzo RV, Underwood PA
1996. The degradation of human endothelial cell
derived perlecan and release of bound basic fibroblast
growth factor by stromelysin, colangenase, plasmin,
and heparenases. J Biol Chem, 271: 10079-10086.
Wilson CL, Heppner KJ, Labosky PA, Hogan BL, Matrisian
LM 1997. Intestinal tumorigenesis is suppressed in
mice lacking the metalloproteinase matrilysin. Proc
Natl Acad Sci USA, 94: 1402-1407.
Wolf M, Clark- Lewis I, Buri C, Langen H, Lis M,
Mazzucchelli L 2003. Cathepsin D specifically
cleaves the chemokines macrophage inflammatory
protein-1 a, macrophage inflammatory protein -
1b, and SLC that are expressed in human breast
cancer. Am J Pathol, 162: 1183- 1190.
Yi Y, Mirosevich J, Shyr Yu, Matsuki R, George A L Jr
2005. Coupled analysis of gene expression and
chromosomal location. Genomics, 85: 401-412.